Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Candesartan cilexetil
Drug ID BADD_D00347
Description Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00796
KEGG ID D00626
MeSH ID C077793
PubChem ID 2540
TTD Drug ID Not Available
NDC Product Code 62559-641; 70771-1207; 17228-0032; 0378-3224; 46708-341; 62559-642; 63629-2126; 62332-341; 62332-342; 68382-191; 68382-193; 70771-1205; 52562-100; 46708-342; 0378-3232; 70771-1206; 46708-060; 46708-343; 60687-119; 60687-130; 62332-343; 17228-0016; 64220-114; 49884-659; 68382-190; 17228-0017; 65372-1128; 49884-658; 63629-2127; 68382-192; 70518-2719; 70518-2884; 60687-241; 62332-060; 62559-643; 0378-3225; 70771-1204; 17228-0018; 72761-002; 49884-661; 62559-640; 0378-3231; 49884-660
UNII R85M2X0D68
Synonyms candesartan cilexetil | 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate | 1H-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- | Parapres | Kenzen | Amias | Blopress | Atacand | TCV 116 | TCV-116
Chemical Information
Molecular Formula C33H34N6O6
CAS Registry Number 145040-37-5
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC 6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.002103%
Leukopenia01.02.02.0010.001262%Not Available
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.0050.002103%Not Available
Loss of consciousness17.02.04.0040.002523%Not Available
Lung disorder22.02.07.0010.001262%Not Available
Lymphadenopathy01.09.01.0020.000841%Not Available
Lymphopenia01.02.02.0020.000841%Not Available
Malaise08.01.01.0030.008999%
Menopausal symptoms21.02.02.002--Not Available
Metabolic acidosis14.01.01.0030.001682%Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.000841%Not Available
Microalbuminuria05.07.02.002; 20.02.01.026; 14.07.02.0020.000841%Not Available
Migraine24.03.05.003; 17.14.02.0010.002523%Not Available
Mitral valve incompetence02.07.01.0020.000841%Not Available
Muscle atrophy17.05.03.004; 15.05.03.003--Not Available
Muscle spasms15.05.03.0040.003364%
Muscle twitching15.05.03.0050.000841%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.005215%
Musculoskeletal pain15.03.04.0070.000841%
Myalgia15.05.02.0010.009672%
Myocardial infarction24.04.04.009; 02.02.02.007--
Myopathy15.05.05.001--Not Available
Myopia06.02.04.002--Not Available
Myositis15.05.01.0010.000841%
Nasal congestion22.04.04.0010.001850%
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.0010.015728%
Neck pain15.03.04.009--
Nephrocalcinosis20.04.01.0010.000841%Not Available
Nephrolithiasis20.04.01.0020.001682%
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 16 Pages